News >

Peregrine Stops Phase III Trial of Bavituximab in NSCLC

Silas Inman @silasinman
Published: Friday, Feb 26, 2016

Steven W. King

Steven W. King

The phase III SUNRISE trial comparing bavituximab plus docetaxel with docetaxel and placebo for patients with non–small cell lung cancer (NSCLC) has been halted following a futility analysis, according the developer of the anionic phospholipids inhibitor, Peregrine Pharmaceuticals.

Shtivelband M, Spigel DR, Gerber DE, et al. Randomized, blinded, placebo-controlled phase II trial of docetaxel and bavituximab as second-line therapy in locally advanced or metastatic non-squamous non-small cell lung cancer. J Clin Oncol. 2013;31 (suppl; abstr 8095).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Community Practice Connections™: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for NursesJun 29, 20191.5
Publication Bottom Border
Border Publication